<DOC>
	<DOCNO>NCT02518763</DOCNO>
	<brief_summary>The vitamin D deficiency ( 25OHD ) common affect 80 % population French osteoporotic woman 50 year [ 5 ] . It contribute significantly bone fragility consequently risk fracture . To remedy deficit , necessary provide suitable sustainable supplementation . Changes vitamin D deficiency range undetectable 25OHD value close 30ng / ml lead difference therapeutic regimen , specific clinician absence precise data literature . No consensus supplementation dosages method propose far . Also , give frequency vitamin D deficiency include osteoporosis observe population , become necessary establish single , uniform regimen patient osteoporosis</brief_summary>
	<brief_title>Vitamin D Supplementation Postmenopausal Women With Osteoporosis : Proposal Therapeutic Regimen Practice</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Postmenopausal woman ≥ 50 year Osteoporosis BMD Tscore ≤ 2.7DS 2.5DS least one two main site analyze , without fracture sign informed consent Taking `` load dose '' vitamin D last six month ( daily intake combination calcium cause exclusion discontinue study ) . Taking osteoporosis treatment combine vitamin D tablet ( Adrovance Fosavance * * ) Treatment thiazide diuretic Known malabsorption ( celiac disease ) Scalable Endocrine disorder : hyperthyroidism , hyperparathyroidism , hypoparathyroidism . Persistent nephrolithiasis occur previous 5 year know sarcoidosis Persons guardianship trusteeship Hypercalcemia hypercalciuria 25OH vitamin D level &gt; 50ng / ml</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>